Illumina announced it will add 50,000 genomes paired with proteomic data to the Alliance for Genomic Discovery (AGD), broadening the alliance’s dataset and enabling integrated genomics‑to‑proteomics discovery for drug targets. Pharmaceutical partners GSK and Amgen are co‑leading the expansion into proteomics, which will be generated by DeCode Genetics using Illumina’s Protein Prep assay. The AGD’s core dataset will grow alongside the recent addition of Regeneron Genetics Center and will now include longitudinal clinical records, strengthening target‑validation capabilities for member companies. Illumina and partners argue that integrated proteogenomic data can accelerate identification of causal mechanisms and therapeutic opportunities. The move underscores industry momentum toward multimodal human data banks to de‑risk target selection and power translational programs across large pharma members.